Raccoon poxvirus live recombinant feline panleukopenia virus VP2 and rabies virus glycoprotein bivalent vaccine

A raccoon poxvirus (RCNV) recombinant for immunizing against feline panleukopenia and rabies was developed by homologous recombination with a chimeric plasmid for insertional inactivation of the RCNV thymidine kinase gene. The recombinant, RCN-FPV/VP2-rabG, coexpressed the feline panleukopenia virus (FPV) VP2 protein and the rabies virus spike glycoprotein (rabG) under oppositely oriented vaccinia virus P11 promoters. Cats vaccinated subcutaneously with the recombinant showed relatively high neutralizing antibody responses against rabies virus and FPV, and protection against an otherwise virulent FPV challenge with no drop in white blood cell count. Because of containment constraints, no rabies virus challenges were done, but the high concentrations (> 8 IU) of rabies neutralizing antibodies were consistent with levels that usually indicate an ability to counter the infection. (C) 1997 Elsevier Science Ltd.